PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER

This Phase 2 study is evaluating a combined surgical and heated chemotherapy treatment — called CRS/HIPEC (cytoreduction surgery followed by hyperthermic intraperitoneal chemotherapy) — for people with stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). **You may be eligible if...** - You are 18 years or older - You have a confirmed diagnosis of adenocarcinoma of the stomach or gastroesophageal junction - Your cancer has spread to the peritoneum (abdominal lining) but may be amenable to surgical removal - Your overall health is adequate for major surgery (ECOG performance status 0-2) - Your blood counts and kidney function meet the study thresholds **You may NOT be eligible if...** - Your cancer has spread beyond the peritoneum to other distant organs (e.g., liver, lungs) - Your overall health or organ function does not support major surgery - Your cancer is too widespread in the abdomen to allow complete surgical removal Talk to your doctor to see if this trial is right for you.